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ABSTRACT
OBJECTIVE: To report the decrease in breast imaging after covid-19 pandemic, obtaining the 
number of mammograms performed in 2019 and 2020. Additionally, to investigate if there was 
an increase in the proportion of women undergoing mammography for diagnostic purposes, 
with palpable lesions.
METHOD: This is a cross-sectional study, based on the number of mammograms performed 
by the Brazilian public health services, provided by DATASUS, an open access database. 
Mammograms from private institutions were not included. This study compares the number 
of mammograms performed in 2019 and 2020, in women aged 50–69 years, stratified by month, 
in each federal state, and the presence of palpable lumps (physician-reported).
RESULTS: In total, 1,948,471 mammograms were performed in 2019 and 1,126,688 in 2020, for 
the population studied. These values represent a 42% decline. Monthly, a significant decreased 
is observed after April 2020. The results varied slightly according to federal state; yet the entire 
country was affected. Rondônia was the most affected state, with 67% decline. The proportion 
of women presenting palpable lumps increased from 7.06% on average in 2019 to 7.94% in 2020 
(OR = 1.135, 95%CI 1.125–1.145, p = 0,001). 
DISCUSSION: The number of mammograms performed in 2020 declined considerably. Out of 
the women who presented for mammogram, the proportion of palpable lumps was significantly 
higher in 2020. Considering the detection rate of digital mammography, the loss of 800,000 
exams means 4,000 undiagnosed breast cancer cases, by the end of 2020. 
DESCRIPTORS: Mammography,  statistics & numerical data.  Breast Neoplasms, diagnosis. 
Coronavirus Infections. State Health Care Coverage.
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INTRODUCTION
In December 2019, Wuhan health authorities exposed that they were treating dozens of 
people with pneumonia, who tested negative for most viruses known to infect humans 
at the time, such as influenza, H1N1, and adenovirus. Typical symptoms included fever, 
cough, dyspnea, and headache; it often progressed to respiratory failure. The pneumonia 
outbreak was attributed to a virus: it was accompanied by leucopenia, diffuse pulmonary 
infiltrates, and no improvement with antibiotics.1 Later, Wuhan researchers were able to 
isolate and sequence the genome of the virus, obtained from seven samples of critically ill 
patients, and they resulted 96% identical to a bat Coronavirus1.
The first cases and deaths outside China were reported in January. The World Health 
Organization (WHO) soon declared it a “Public Health Emergency of International 
Concern (PHEIC)”2, and named the disease as covid-19, an acronym for “Coronavirus 
disease 2019”3. As of January 2021, there have been approximately 95 million cases and 
2 million deaths worldwide; Brazil is the third most affected country, with 8.5 million 
cases and 200 thousand deaths4. 
Many authorities, governors and rulers followed Wuhan restrictive measures (known as 
total or partial “lockdown”), to contain the spread of the virus. On March 21st, the Governor 
of São Paulo state João Doria decreed quarantine for all the 645 cities within the state5. 
He was then followed by other Governors. On March 17th, the Brazilian National Health 
Agency (Agência Nacional de Saúde – ANS) recommended that “visits, exams or surgeries 
that do not apply as urgent” should be postponed6. 
Breast cancer is the leading cause of death by cancer among women in Brazil, and the fifth 
among all causes (preceded by heart attack, pneumonia, diabetes, and chronic obstructive 
pulmonary disease)7. There are nearly 66,000 new breast cancer cases each year8. Globally, 
Brazil is still struggling to increase its survival rates. Even comparing to its neighbor 
Argentina, Brazil has much to improve. Global data reveals that, from 2010 to 2014, Brazil 
had breast cancer survival rates of 75.2%, compared to 84.4% in Argentina. Most European 
countries, as well as Japan, Australia, New Zealand, Canada, and the United States had 
five-year survival rates greater than 85%9. 
In Brazil, the standard screening program for public health system is for women aged 
from 50 to 69 years, every two years10. Nevertheless, most private institutions prefer the 
recommendation from Brazilian Radiology College, to perform mammogram annually, 
after 40 years old, until good health11. It is estimated that screening coverage in Brazil, 
combining public and private care, is only 60% of the aimed population, approximately12. 
This study reports the decrease in breast imaging after covid-19 pandemic, obtaining the 
number of mammograms performed in 2019 and 2020. Furthermore, it investigates if there 
was an increase in the proportion of women undergoing mammography for diagnostic 
purposes, with palpable lesions.
METHODS
This is a cross-sectional study, based on the number of mammograms performed by 
the Brazilian public health care, as provided by DATASUS, an open access database. 
Mammograms from private institutions were not included. Brazil has many private health 
services, whose data are not available at DATASUS. 
When requesting for mammograms, after clinical history is obtained and physical exam 
completed, the physician or health care provider is supposed to answer the following 
questions on the cover of the request: 
1. Does the patient have a lump in the breast?
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2. Is the patient at high risk for breast cancer?
3. Has the patient ever had the breasts examined by a health care professional?
4. Has the patient ever had a mammogram?
5. Has the patient ever had breast radiotherapy?
6. Has the patient ever had a breast surgery?
7. Diagnostic mammogram (here the physician or health care professional is supposed to 
indicate the location and type of symptomatic lesion – lump, thickening or discharge). 
8. Screening mammogram (here the professional indicates if the patient is from regular 
or high-risk population). 
All the questions have multiple-choice answers. The questionnaire is digitalized, and then 
sent to the national database.
In this study the number of mammograms will be the focus, especially those with answers 
“YES” for the first question – “Does the patient have a lump in the breast?”, as reported by 
the physician or health care provider.
This study compares the number of mammograms performed in 2019 and 2020, at the 
Brazilian Unified Health System (SUS), in women aged from 50 to 69 years old – the main 
population from breast cancer screening in Brazil. The coverage of exams provided by SUS 
will be calculated, dividing that number from the population of women aged 50–69 years 
old. Then, the numbers will be stratified by month, in each federal state, and by the presence 
of palpable lumps. These will be named “YES” patients. 
Tables and Graphs were built with Microsoft Office Excel®. Odds Ratio values were obtained 
with the aid of Graph Pad Prism version 9 for MacOS; and they were considered significant 
if p < 0.05.
Table 1. Mammography coverage (SUS), in women aged 50–69y, 2019–2020, Brazil.
Year Mammograms Population Coverage (%)
2019 1,948,471 20,636,636 9.44%
2020 1,126,688 21,140,958 5.33%
SUS: Brazilian Unified Health System.
Table 2. Mammograms by patient (SUS), in women aging 50–69y, 2019–2020, Brazil.
Month 2019 2020 Reduction (%)
Total 1.948.471 1.126.688 - 42,18%
January 149.053 152.526 + 2,33%
February 151.453 143.099 - 5,52%
March 144.763 135.000 - 6,74%
April 154.395 37.016 - 76,03%
May 155.700 27.381 - 82,41%
June 140.324 37.313 - 73,41%
July 148.190 47.528 - 67,93%
August 153.784 57.053 - 62,90%
September 158.140 77.136 - 51,22%
October 214.514 135.274 - 36,94%
November 199.783 160.616 - 19,60%
December 178.372 116.746 - 34,55%
SUS: Brazilian Unified Health System.
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RESULTS
In total, 1,939,415 mammograms were performed in 2019 and 1,126,688 in 2020, for 
the studied population (Table 1). These values represent a 42% decline. SUS provided 
mammograms for 9.4% of women in 2019, and 5.3% in 2020. 
Table 2 shows the number of mammograms performed each month. It is observed that 
2020 started well, with increased rates of mammography performed in January. Then, 
it declined slightly in February and March; and sharply from April forward, after restrictive 
measures were announced. 
Table 3 shows the same data distributed by the presence of palpable lumps, according 
to the report from the health care provider. For each year, the table presents the 
number of mammograms from “YES” patients (with palpable lumps), the total number 




YES Total Fraction YES Total Fraction
January 9,919 149,053 6.65% 10,614 152,526 6.96%
February 10,450 151,453 6.90% 10,189 143,099 7.12%
March 10,028 144,763 6.93% 9,583 135,000 7.10%
April 11,144 154,395 7.22% 3,020 37,016 8.16%
May 11,316 155,700 7.27% 2,680 27,381 9.79%
June 10,093 140,324 7.19% 3,824 37,313 10.25%
July 10,926 148,190 7.37% 5,082 47,528 10.69%
August 11,145 153,784 7.25% 5,519 57,053 9.67%
September 11,687 158,140 7.39% 7,215 77,136 9.35%
October 14,994 214,514 6.99% 10,829 135,274 8.01%
November 13,707 199,783 6.86% 12,116 160,616 7.54%
December 12,161 178,372 6.82% 8,737 116,746 7.48%
Total 137,570 1,948,471 7.06% 89,408 1,126,688 7.94%


































































































YES = with palpable lumps; SUS: Brazilian Unified Health System.
Graph 1. Mammograms by patient (SUS), in women aged 50–69y, 2019–2020, Brazil.
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of mammograms (with or without palpable lumps), and the fraction of “YES” patients. 
Although the total number of mammograms decreased, it is observed an increase in the 
proportion of patients with palpable lumps. In total, 7.06% of patients had palpable lumps 
in 2019, and 7.94% in 2020 (OR = 1.135, 95%CI 1.125–1.145, p = 0,001). Graph 1 shows the 
same data imaged.
Lastly, mammograms performed in each federal state were obtained. Results are 
presented in Table 3. The total numbers are slightly different from Table 2, because not 
every mammograms presented information about location. 
DISCUSSION
The covid-19 pandemic has hindered breast cancer diagnosis in Brazil. The number of 
mammograms performed in 2020 declined considerably. Out of those women who did 
perform a mammogram examination, the proportion of palpable lumps was significantly 
higher in 2020. Based on this information, two assumptions can be done: that women 
postponed breast cancer screening; and that, even symptomatic, some may have chosen 
not to undergo mammogram or did not have access to it. 
Table 4. Mammograms by patient (SUS), according to federal state, in women aged 50–69y, 
2019–2020, Brazil.
Federal State 2019 2020 Reduction (%)
Total 1,939,423 1,126,565 -42%
Rondônia 10,017 3,316 -67%
Acre 2,813 2,694 -4%
Amazonas 10,936 7,851 -28%
Roraima 2,870 1,858 -35%
Pará 29,316 26,350 -10%
Amapá 1,699 2,331 +37%
Tocantins 7,040 4,008 -43%
Maranhão 23,921 18,371 -23%
Piauí 12,073 12,039 0%
Ceará 57,934 39,043 -33%
Rio Grande do Norte 36,264 22,586 -38%
Paraíba 43,842 27,490 -37%
Pernambuco 136,895 66,009 -52%
Alagoas 49,228 32,990 -33%
Sergipe 27,228 12,702 -53%
Bahia 185,453 99,531 -46%
Minas Gerais 320,496 178,949 -44%
Espírito Santo 66,095 34,524 -48%
Rio de Janeiro 56,970 37,326 -34%
São Paulo 288,372 177,359 -38%
Paraná 213,870 114,605 -46%
Santa Catarina 106,720 59,888 -44%
Rio Grande do Sul 131,096 86,095 -34%
Mato Grosso do Sul 33,655 13,503 -60%
Mato Grosso 20,489 8,962 -56%
Goiás 53,580 27,980 -48%
Distrito Federal 10,640 8,347 -22%
SUS: Brazilian Unified Health System.
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Rondônia was the most affected state, with a 67% decrease in the number of mammograms 
performed. São Paulo, the most populated state, had overall 38% decline. Piauí stands as the 
least affected, with no decline at all. It is reasonable to exclude Amapá from any analysis: 
although it counted 37% more exams, it still has the lowest absolute number – probably due 
to documentation inaccuracies. The purpose of showing data from different states was not 
to determine whether one specific state had a statistically significant different outcome, 
but to show that the pandemic has affected the entire country. Southeast states (São Paulo, 
Rio de Janeiro, Minas Gerais, and Espírito Santo) have the best rates of screening coverage 
(67.9% compared to national 60%)12, but nevertheless they were as much, or even more, 
affected as other poorer states.
This study has pitfalls. A major concern is that it does not include data from private health 
care. If nationwide screening coverage is about 60%, and the population of women aged from 
50 to 69 years old is close to 20 million, it is possible that more than 10 million mammograms 
performed are missing. Also, these data are dependent on the physician’s ability to fill the 
request appropriately. On the positive side, the results fulfill the purpose to document how 
the pandemic affected breast cancer diagnosis, although partially.
It is controversial whether screening programs increase survival in low-income countries. 
It is known that survival depends on tumor stage at diagnosis, with five-year rates of 99% 
for localized, 86% for regional, and 27% for distant disease13. Regular screening programs 
lower the rates of advanced disease at diagnostics14. A Cochrane meta-analysis showed 
significant increase in breast cancer survival with mammographic screening (RR 0.81, 
CI 0.74 to 0.87)15. However, studies were from Canada, the United States, United Kingdom, 
Sweden, and Scotland. In Brazil, unfortunately, the screening program has little effect at 
decreasing advanced disease and increasing survival. There are many other barriers to 
appropriate treatment. For example, the mean time between breast cancer presentation 
and biopsy on SUS is between 75–185 days16. Most operable cases are diagnosed in later 
stages (53.5% stage 2 and 23.2% stage 3)17. Some authors advocate that the best strategy for 
Brazil is prompt care for symptomatic patients18. However, a recent study found that, when 
diagnosed at early stages, survival rates in Brazil are greater than 90%19. This means that, 
despite all difficulties, Brazil’s health authorities must not give up pursuing early detection 
for breast cancer.
Note that Graph 1 shows the effect of the “Outubro Rosa” campaign, to promote breast 
cancer awareness and screening. October is, indeed, the month with most mammograms 
performed throughout the year, and it had a positive effect in 2020 to relieve the 
pandemic scenario. 
Considering that the average detection rate of breast cancers for digital mammography 
is 5/1,00020, the loss of 800,000 exams during the year of 2020 means 4,000 undetected 
breast cancers – and this value only addresses SUS patients. This represents a potential 
burden of advanced disease for the next years.
Worsening breast cancer rates of detection and survival will be a painful and costly side 
effect of the pandemic. ANS should exclude breast cancer screening and diagnosis from 
the postponement recommendation. It should be made clearer to the population that 
services related to the diagnosis and treatment of breast cancer are not considered as 
“consultations, exams or surgeries that do not apply as urgent.” For the future, we may 
learn that breast cancer screening should never again be postponed, but adapted to any 
new crisis, pandemics, or situations.
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